Disulfonate stilbenes for use in the treatment of proliferative diseases
Compounds of general formula: wherein R 0A and R 0B are independently selected from hydrogen and pharmaceutically acceptable cations; and R A and R B are identical and selected from amide, carbamate, sulphonamide, azido, cyano and halide. Also, a pharmaceutical composition including one of the compounds. The composition may also include another active ingredient, especially an antineoplastic agent. Further a compound or a composition for use as a medicament, especially a compound or a composition for use in the treatment of a proliferative disease such as for example cancer.
1. A method of treatment of a cancer in a subject in need thereof, wherein the method comprises a step of administration to the subject of a compound of Formula (I)
wherein:
R 0A and R 0B are independently selected from the group consisting of hydrogen, lithium, sodium, and potassium; and
R A and R B are identical and selected from the group consisting of —NH—COOR, azido, cyano, and halide;
wherein each R is independently selected from the group consisting of (C 1 -C 4 )-alkyl and phenyl;
wherein the phenyl is optionally substituted by one or two substituent(s) independently selected from the group consisting of (C 1 -C 3 )-alkyl, (C 1 -C 3 )-alkoxy, and nitro;
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the phenyl is optionally substituted by one or two substituent(s) independently selected from the group consisting of methyl, methoxy, and nitro.
3. The method according to claim 1 , wherein R A and R B are —NH—COOR, wherein each R is independently selected from the group consisting of (C 1 -C 4 )-alkyl and phenyl; wherein the phenyl is optionally substituted by one or two substituent(s) independently selected from the group consisting of (C 1 -C 3 )-alkyl, (C 1 -C 3 )-alkoxy, and nitro.
4. The method according to claim 1 , wherein R A and R B are selected from azido, cyano, and halide.
5. The method according to claim 1 , wherein the halide is iodine.
6. The method according to claim 1 , wherein both R 0A and R 0B are sodium or wherein both R 0A and R 0B are potassium.
7. The method according to claim 1 , wherein the compound of Formula (I) is selected from:
and pharmaceutically acceptable salts thereof.
8. The method according to claim 1 , wherein said cancer is breast cancer, glioblastoma, or multiple myeloma.
9. The method according to claim 1 , comprising a step of administration to the subject of a composition, wherein the composition comprises the compound of Formula (I) and a pharmaceutically acceptable excipient.
10. The method according to claim 9 , wherein the composition further comprises at least another active ingredient.
11. The method according to claim 10 , wherein the at least another active ingredient is an antineoplastic active ingredient.